Evaluation of Hepatitis C Screening and Treatment Among Psychiatry Inpatients

References (34)

1. Kwong JC, Ratnasingham S, Campitelli MA, et al. The impact of infection on population health: results of the Ontario Burden of Infectious Diseases Study. PLoS One. 2012;7(9):e44103. PubMed CrossRef
2. Popovic N, Williams A, Périnet S, et al. National hepatitis C estimates: Incidence, prevalence, undiagnosed proportion and treatment, Canada, 2019. Can Commun Dis Rep. 2022;48(11/12):540–549. CrossRef
3. Hughes E, Bassi S, Gilbody S, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry. 2016;3(1):40–48. PubMed CrossRef
4. Trager E, Khalili M, Masson CL, et al. Hepatitis C screening rate among underserved adults with serious mental illness receiving care in California community mental health centers. Am J Public Health. 2016;106(4):740–742. PubMed CrossRef
5. Sylvestre DL, Loftis JM, Hauser P, et al. Co-occurring Hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health. 2004;81(4):719–734. PubMed CrossRef
6. Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology. 2007;46(4):991–998. PubMed CrossRef
7. Tang LS, Masur J, Sims Z, et al. Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment. World J Hepatol. 2016;8(31):1318–1326. PubMed CrossRef
8. Mandel E, Underwood K, Masterman C, et al. Province to province variability in hepatitis C testing, care, and treatment across Canada. Can Liver J. Forthcoming.
9. Miarons M, Sánchez-Ulayar A, Sempere G, et al. New direct-acting antivirals for hepatitis C treatment and neuropsychiatric symptoms in psychiatric risk groups. Eur J Hosp Pharm Sci Pract. 2019;26(3):135–139. PubMed CrossRef
10. Hauser P, Kern S. Psychiatric and substance use disorders co-morbidities and hepatitis C: diagnostic and treatment implications. World J Hepatol. 2015;7(15):1921–1935. PubMed CrossRef
11. Paisi M, Crombag N, Burns L, et al. Barriers and facilitators to hepatitis C screening and treatment for people with lived experience of homelessness: a mixed-methods systematic review. Health Expect. 2022;25(1):48–60. PubMed CrossRef
12. Kattakuzhy S, Gross C, Emmanuel B, et al; ASCEND Providers. Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial. Ann Intern Med. 2017;167(5):311–318. PubMed CrossRef
13. Cuadrado A, Llerena S, Cobo C, et al. Microenvironment eradication of hepatitis C: a novel treatment paradigm. Am J Gastroenterol. 2018;113(11):1639–1648. PubMed CrossRef
14. Chhatwal J, Chen Q, Bethea ED, et al. The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. Aliment Pharmacol Ther. 2019;50(1):66–74. PubMed CrossRef
15. World Health Organization. Combating Hepatitis B and C to Reach Elimination by 2030: Advocacy Brief. May 2016. https://apps.who.int/iris/bitstream/handle/10665/206453/WHO_HIV_2016.04_eng.pdf?sequence=1&isAllowed=y
16. Wade AJ, Doyle JS, Gane E, et al. Outcomes of treatment for hepatitis C in primary care, compared to hospital-based care: a randomized, controlled trial in people who inject drugs. Clin Infect Dis. 2020;70(9):1900–1906. PubMed CrossRef
17. Roder C, Nguyen P, Harvey C, et al. Psychiatrists can treat hepatitis C. J Viral Hepat. 2021;28(12):1763–1764. PubMed CrossRef
18. Aldridge RW, Story A, Hwang SW, et al. Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis. Lancet. 2018;391(10117):241–250. PubMed CrossRef
19. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32–36. PubMed CrossRef
20. Sterling RK, Lissen E, Clumeck N, et al; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325. PubMed CrossRef
21. McNeish D. Missing data methods for arbitrary missingness with small sample. J Appl Stat. 2015;44(1):24–39. CrossRef
22. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30(4):377–399. PubMed CrossRef
23. Shah H, Bilodeau M, Burak KW, et al; Canadian Association for the Study of the Liver. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ. 2018;190(22):E677–E687. PubMed CrossRef
24. Crismale JF, Ahmad J. Expanding treatment for hepatitis C in Canada. CMAJ. 2018;190(22):E667–E668. PubMed CrossRef
25. Mandel E, Peci A, Cronin K, et al. The impact of the first, second and third waves of COVID-19 on hepatitis B and C testing in Ontario, Canada. J Viral Hepat. 2022;29(3):205–208. PubMed CrossRef
26. Wolfson-Stofko B, Karkada J, Vanderhoff A, et al. The hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics. Presented at INHSU 2021; October 13–15, 2021. Ontario, Canada.
27. Biondi MJ, Hirode G, Capraru C, et al. Birth cohort hepatitis C antibody prevalence in real-world screening settings in Ontario. Can Liver J. 2022;5(3):362–371. PubMed CrossRef
28. Schillie S, Wester C, Osborne M, et al. CDC recommendations for hepatitis C screening among adults — United States, 2020: recommendations and reports. MMWR Recomm Rep. 2020;69(2):1–17. PubMed
29. Le E, Chee G, Kwan M, et al. Treating the hardest to treat: reframing the hospital admission as an opportunity to initiate hepatitis C treatment. Dig Dis Sci. 2022;67(4):1244–1251. PubMed CrossRef
30. Valerio H, Alavi M, Law M, et al. Opportunities to enhance linkage to hepatitis C care among hospitalized people with recent drug dependence in New South Wales, Australia: a population-based linkage study. Clin Infect Dis. 2021;73(11):2037–2044. PubMed CrossRef
31. Younossi Z, Park H, Henry L, et al. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016;150(7):1599–1608. PubMed CrossRef
32. Yarlott L, Heald E, Forton D. Hepatitis C virus infection, and neurological and psychiatric disorders: a review. J Adv Res. 2017;8(2):139–148. PubMed CrossRef
33. Hilsabeck RC, Hassanein TI, Carlson MD, et al. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc. 2003;9(6):847–854. PubMed CrossRef
34. Cooper CL, Galanakis C, Donelle J, et al. HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study. BMC Infect Dis. 2019;19(1):712. PubMed CrossRef